Physician profile
Richard D Schultz
NPI 1124029137
$502.48
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $75.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109.22 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $108.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $41.11 | 2019 | |
| Abbott Laboratories | $31.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $29.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.05 | 2019 | |
| Pfizer INC. | $22.63 | 2019 | |
| Lundbeck LLC | $21.37 | 2019 | |
| Abiomed | $20.33 | 2020 | |
| Quidel Corporation | $16.69 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.54 | 2019 | |
| Astellas Pharma US INC | $13.73 | 2019 | |
| Irhythm Technologies, INC. | $12.61 | 2019 | |
| Boston Scientific Corporation | $12.22 | 2019 | |
| Nuwellis, INC. | $12.16 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.